← Leaderboards
Eirini Papapetrou
Sloan-Kettering Inst Can Research
$13,419,805
Attributed
$16,617,008
Total exposure
8
Grants
8
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2M · FY2011–25$2.5M$1.9M$1.3M$625K$0
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$16,617,008 · 8
By mechanism
R01$15,677,258 · 6
R00$759,750 · 1
K99$180,000 · 1
Top collaborators
- Michael Kharas5 shared
- Eugene Wei-Ming Yeo4 shared
Most similar at Sloan-Kettering Inst Can Research
Same institution · by research overlap
- Olga A Guryanova$2,670,428
- Aaron D Viny$3,272,036
- Ross L Levine$31,715,816
- Jacob Lowell Glass$1,421,573
- Sheng Cai$1,444,218
Others in their field
Top investigators on “Cells”
- Lawrence Corey · Fred Hutchinson Cancer Center$536,344,731
- Barton F Haynes · Duke University$457,457,619
- David Heimbrook · Leidos Biomedical Research, Inc.$454,789,509
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$299,104,942
- Dennis R. Burton · Scripps Research Institute$278,781,854
- Mary M Horowitz · Medical College Of Wisconsin$237,383,608
Research focus
CellsInduced Pluripotent Stem CellMediatingGenesHematopoieticIn VitroCell LineGeneticClustered Regularly Interspaced Short Palindromic RepeatsBone MarrowEngineeringMutationLaboratoriesPathway InteractionsMalignant NeoplasmsLeukemiaMolecularAffectInsightAcute Myelocytic LeukemiaBaseGenomeMethodologyMutant
Grant awards (32)
Mechanisms and targeting of aberrant Gas activation in myeloid neoplasms$677,959
R01 · FY2025 · CA · contact PI
Mechanisms and therapeutic implications of human clonal hematopoiesis (CH) mutations$671,875
R01 · FY2025 · CA · contact PI
Impact of mutational order on molecular mechanisms of oncogenesis$648,012
R01 · FY2025 · CA · contact PI
Mechanisms and therapeutic implications of human clonal hematopoiesis (CH) mutations$638,281
R01 · FY2024 · CA · contact PI
Mechanisms and targeting of aberrant Gas activation in myeloid neoplasms$637,399
R01 · FY2024 · CA · contact PI
Impact of mutational order on molecular mechanisms of oncogenesis$615,612
R01 · FY2024 · CA · contact PI
Mechanisms and targeting of aberrant Gas activation in myeloid neoplasms$670,945
R01 · FY2023 · CA · contact PI
Mechanisms and therapeutic implications of human clonal hematopoiesis (CH) mutations$658,437
R01 · FY2023 · CA · contact PI
Impact of mutational order on molecular mechanisms of oncogenesis$635,052
R01 · FY2023 · CA · contact PI
Mechanisms and therapeutic implications of human clonal hematopoiesis (CH) mutations$689,125
R01 · FY2022 · CA · contact PI
Impact of mutational order on molecular mechanisms of oncogenesis$665,262
R01 · FY2022 · CA · contact PI
Identification of therapeutic targets for leukemia stem cells in AML-iPSC models$652,184
R01 · FY2022 · CA · contact PI
Identification of therapeutic targets for leukemia stem cells in AML-iPSC models$654,506
R01 · FY2021 · CA · contact PI
Dissecting splicing factor mutations in iPSCs$788,895
R01 · FY2020 · HL · contact PI
Identification of therapeutic targets for leukemia stem cells in AML-iPSC models$658,908
R01 · FY2020 · CA · contact PI
Dissecting splicing factor mutations in iPSCs$796,490
R01 · FY2019 · HL · contact PI
Identification of therapeutic targets for leukemia stem cells in AML-iPSC models$586,205
R01 · FY2019 · CA · contact PI
Dissecting splicing factor mutations in iPSCs$803,727
R01 · FY2018 · HL · contact PI
Identification of therapeutic targets for leukemia stem cells in AML-iPSC models$625,414
R01 · FY2018 · CA · contact PI
Modeling chromosome 7 loss in Myelodysplasia-iPSCs$423,750
R01 · FY2018 · HL · contact PI
Dissecting splicing factor mutations in iPSCs$828,077
R01 · FY2017 · HL · contact PI
Modeling chromosome 7 loss in Myelodysplasia-iPSCs$423,750
R01 · FY2017 · HL · contact PI
Modeling chromosome 7 loss in Myelodysplasia-iPSCs$423,750
R01 · FY2016 · HL · contact PI
Modeling chromosome 7 loss in Myelodysplasia-iPSCs$417,393
R01 · FY2015 · HL · contact PI
Genetic correction of human beta-thalassemic induced pluripotent stem cells$249,000
R00 · FY2015 · DK · contact PI
Modeling chromosome 7 loss in Myelodysplasia-iPSCs$386,250
R01 · FY2014 · HL · contact PI
Genetic correction of human beta-thalassemic induced pluripotent stem cells$144,075
R00 · FY2014 · DK · contact PI
Genetic correction of human beta-thalassemic induced pluripotent stem cells$117,675
R00 · FY2014 · DK · contact PI
Genetic correction of human beta-thalassemic induced pluripotent stem cells$249,000
R00 · FY2013 · DK · contact PI
Genetic correction of human beta-thalassemic induced pluripotent stem cells$90,000
K99 · FY2012 · DK · contact PI
Genetic correction of human beta-thalassemic induced pluripotent stem cells$47,880
K99 · FY2011 · DK · contact PI
Genetic correction of human beta-thalassemic induced pluripotent stem cells$42,120
K99 · FY2011 · DK · contact PI